AstraZeneca and MedImmune presented results from the Phase III 1053 clinical trial that evaluated CAT 8015 (moxetumomab pasudotox) in 80...
LEO Pharma announced that CAT 354 (tralokinumab) met all primary and secondary endpoints in its three pivotal Phase III studies...
The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous thromboembolism (VTE) in patients with active cancer who have completed at least 6 months of anticoagulant therapy...
Circassia Pharmaceuticals plc announced top-line results from its investigational cat allergy immunotherapy phase III study. In the study, both treatment...
Theravance Biopharma, Inc. and Mylan N.V. announced the presentation of additional positive efficacy data from the three-month, pivotal Phase III...